MedTrace Logo

A Study of ACI-24 in Adults With Down Syndrome

NCT04373616 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-10-22

No results posted yet for this study

Summary

This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.

Conditions

  • Down Syndrome

Interventions

BIOLOGICAL

ACI-24

injections

BIOLOGICAL

Placebo

injections

Sponsors & Collaborators

  • AC Immune SA

    lead INDUSTRY

Principal Investigators

  • Michael S. Rafii, MD, PhD · Alzheimer's Therapeutic Research Institute USC Keck School of Medicine of the University of Southern California, San Diego, CA, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2024-04-30
Completion
2024-10-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04373616 on ClinicalTrials.gov